Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Sanofi
• Treatments: Irbesartan

Criteria

Inclusion Criteria:

• Recurrent PAF with indication for catheter ablation

Exclusion Criteria:

• Struct. Cardiopathy

• Mitral valve disease

• VEF<40%

• Myocardiopathy

• LVH

• cardiac surgery

• AF reversible

• QT c>450

• Recent MI/stroke, severe HTN

• Requirement of ACEI/ARBs

• Coronary synd., HTA, liver disease